STAT

MARCH 15, 2024

A symphony of synapses fires every time a songbird sings. For Erich Jarvis, a neurobiologist at Rockefeller University, the neural pathways he finds particularly interesting inside a birds’ brain are those that enable the bird to make new sounds from listening to their environment. This is an ability known as vocal learning, and is perhaps most notably exhibited when a parrot mimics a person’s speech (or profanity).

338

338

PharmaVoice

MARCH 15, 2024

The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.

300

300

STAT

MARCH 15, 2024

A panel of expert advisers to the Food and Drug Administration on Friday voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about the powerful treatment’s side effects. The group voted 11-0 that the benefits of Carvykti, a CAR-T medicine from Johnson & Johnson and Legend Biotech, outweighed its risk for patients with multiple myeloma whose disease has persisted despite initial treatment.

312

312

ALiEM - Pharm Pearls

MARCH 15, 2024

A 28-year-old male presented to the ED for evaluation of an injury to his right eye. While working out with an exercise band, it snapped back, hitting the patient in the right eye. He experienced blurry vision and excess eye tearing immediately after the incident occurred. The patient also developed gross blood over the front of the eye. Physical Exam Vitals : Temp 98°F, HR 73, BP (135/77), RR 16, SpO2 99% HEENT : Gross blood in the anterior portion of the right eye (grade I).

158

158

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

MARCH 15, 2024

Scientists are taught early in our training that criticism is a fundamental part of the job. What we are not usually trained to navigate, however, is public backlash, which is exactly what followed the publication of the comprehensive genomic sequencing results from the All of Us Research Program. The study aims to add the genomic information of 1 million volunteers from normally underrepresented genetic backgrounds to datasets that have been mostly constituted by people of European descent.

307

307

BioPharma Dive

MARCH 15, 2024

The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.

120

120

The Pharmacist

MARCH 15, 2024

Pharmacy contractors now have until 11.59pm on Thursday 21st March 2024 to submit their payment claims for Pharmacy First services delivered in February, the NHS Business Services Authority (NHSBSA) has announced. It added that contractors should still receive their Pharmacy First payment on 1 May 2024 if they submit their February claim by the revised […] The post Pharmacy First payment submission deadline extended again amid IT issues appeared first on The Pharmacist.

110

110

STAT

MARCH 15, 2024

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them.  Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

217

217

pharmaphorum

MARCH 15, 2024

Popular mobile messaging apps that offer end-to-end encryption for their users' communications means that the content of messages is only accessible to the sender and the recipient. However, like any software, they still have potential cybersecurity risks and compliance concerns that users should be aware of - especially in pharma.

Communication 117

Communication 117

STAT

MARCH 15, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hey there. Today, we see the first approval of a drug to treat MASH, a Gilead medication shows huge promise in Ebola, and more.

Drug Pricing 211

Drug Pricing Drug Development 211

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

MARCH 15, 2024

Explore the latest digital and supplier hires in the pharmaceutical industry, including Campbell, EMS Healthcare, PhRMA, and Exscientia in February 2024. Stay updated on the changing faces in industry.

110

110

STAT

MARCH 15, 2024

And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is vague, at the moment. We hope to hang with our fast-moving short person, albeit briefly, promenade with the official mascots, and hold a listening party, where the rotation will likely include this , this , this , this and this.

Drug Pricing 180

Drug Pricing Biosimilars Diabetes 180

World Pharma News

MARCH 15, 2024

Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world's leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.

Hospitals 105

Hospitals 105

Board Vitals - Pharmacist

MARCH 15, 2024

You’ve worked tirelessly through years of medical school, and the culmination of your efforts has finally arrived: the residency match. While you may be excited to have matched, it can be disappointing to realize you matched into a program lower on your preference list, especially as watch your classmates celebrate their own successes. It’s okay to feel disappointed, and it’s natural to have envisioned a different outcome after investing so much time and effort into your medica

Medical Schools 105

Medical Schools 105

Pharmaceutical Commerce

MARCH 15, 2024

Reliance on foreign imports means that disruptions in the supply chain can profoundly impact the ability of individuals in the United States to get access to the medications they need.

105

105

Pharmafile

MARCH 15, 2024

The US Food and Drug Administration (FDA) has announced that it has approved Rezdiffra (resmetirom) for the treatment of adult patients with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), for use alongside diet and exercise. This approval follows an analysis of the safety and efficacy of the drug based on a […] The post FDA approves first treatment for liver scarring due to fatty liver disease appeared first on Pharmafile.

105

105

pharmaphorum

MARCH 15, 2024

Our latest round-up of funding rounds in the digital health category features updates from Healthee, Aktiia, Moxe Health, Eleanor Health, Tava Health, BrainCheck, and Redi Health.

96

96

Express Pharma

MARCH 15, 2024

Shift could reflect a changing demand away from oncology toward addressing metabolic disorders GLP1 agonist drugs transformed the weight loss and diabetes landscape in 2023, propelled by robust clinical trial results and a surge in endorsements from celebrities and influencers. While PD1 antagonist drugs currently reign as the top-selling drug class, this status quo is poised for a shift.

Diabetes 97

Diabetes Compounding 97

pharmaphorum

MARCH 15, 2024

The ALS Association is partnering with myTomorrows to connect patients and physicians with clinical trials using a digital platform.

109

109

Express Pharma

MARCH 15, 2024

Health activists raise doubts on pharma associations self-monitoring the code The notification of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 on March 12 has been welcomed by major pharma associations, while health activists allege it is a “whitewash.” The notification directs all associations to constitute an Ethics Committee for Pharmaceutical Marketing Practices (ECPMP), set up a dedicated UCPMP portal on their website, and take further necessary steps tow

Pharmaceutical Manufacturing 91

Pharmaceutical Manufacturing Communication Pharmaceutical Companies Pharmaceutical Companies 91

pharmaphorum

MARCH 15, 2024

Consortium led by Birmingham University unveils a centre of excellence for medicines manufacturing training using VR, to answer a UK skills shortage.

99

99

Pharmaceutical Technology

MARCH 15, 2024

Amidst the many BTK inhibitors, Breyanzi will be the first and only CAR-T cell therapy available for the treatment of CLL and SLL.

105

105

Pharma Times

MARCH 15, 2024

More than 3,700 cases of mpox have been identified in the UK since May 2022

Vaccines 124

Vaccines 124

European Pharmaceutical Review

MARCH 15, 2024

According to research published by Coherent Market Insights, the global mycoplasma testing market is anticipated to reach $1,907.6 million by 2031. The market is set to witness a compound annual growth rate (CAGR) of 9.7 percent during the forecast period, the report predicted. What is driving and limiting growth in the market? Specifically, technology innovations such as sequencing technology, supported by “strong government funding for biomedical research” in the US has driven rapid developmen

Compounding 86

Compounding 86

pharmaphorum

MARCH 15, 2024

Madrigal Pharma is first pharma company to get FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH)

98

98

BioPharma Dive

MARCH 15, 2024

A majority of experts believed that the factors that may have led to an increased risk of early death in testing of Carvykti and Abecma aren’t as likely to occur outside of a clinical trial.

87

87

Pharmaceutical Technology

MARCH 15, 2024

Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.

97

97

Drug Channels

MARCH 15, 2024

Today’s guest post comes from Josh Marsh, Vice President and General Manager of Sonexus™ Access and Patient Support at Cardinal Health. Josh discusses factors that drive manufacturers to insource versus outsource patient support services. He shares data from a Cardinal Health survey of biopharmaceutical companies and offers four factors to consider when evaluating your patient support program.

76

76

European Pharmaceutical Review

MARCH 15, 2024

Researchers have proposed an advanced analytical technology that can rapidly classify medical cannabis plants at production sites. Using the analytical technique, the plants can be classified “by chemotype using hyperspectral imaging and machine learning (ML),” Markel San Nicolas, researcher in the UPV/EHU’s IBeA group of the University of the Basque Country, and first author of the corresponding research paper explained.

78

78

Pharmaceutical Technology

MARCH 15, 2024

Madrigal’s Rezdiffra received an accelerated approval as a treatment for noncirrhotic NASH, also known as MASH.

98

98

Pharmaceutical Commerce

MARCH 15, 2024

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

Biosimilars 105

Biosimilars 105

pharmaphorum

MARCH 15, 2024

Geron rockets after FDA advisory committee backs imetelstat as a treatment for transfusion-dependent myelodysplastic syndromes

90

90

Pharma Times

MARCH 15, 2024

Every year, missed hospital appointments are estimated to cost the NHS £1.

Hospitals 108

Hospitals 108

BioPharma Dive

MARCH 15, 2024

Sold as Breyanzi, the therapy is now cleared for use in certain adults with hard-to-treat forms of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

68

68

Drug Patent Watch

MARCH 15, 2024

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.

69

69